Notification and public disclosure of transactions by persons discharging managerial responsibilities
The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.
Said Darwazah
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
Said Darwazah |
2 |
Reason for the notification |
|
a) |
Position/status |
Chairman and Chief Executive Officer / PDMR |
b) |
Initial notification /Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Hikma Pharmaceuticals PLC |
b) |
LEI |
549300BNS685UXH4JI75 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
b) |
Nature of the transaction
|
Acquisition by Darhold Limited of 155,991 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%. |
c) |
Price(s) and volume(s) |
Price(s): £21.94 Volume(s): 155,991 |
d) |
Aggregated information |
Aggregated volume: 155,991 Price: £21.94 |
e) |
Date of the transaction |
6 September 2016 |
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Mazen Darwazah
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
Mazen Darwazah |
2 |
Reason for the notification |
|
a) |
Position/status |
Executive Vice Chairman / PDMR |
b) |
Initial notification /Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Hikma Pharmaceuticals PLC |
b) |
LEI |
549300BNS685UXH4JI75 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
b) |
Nature of the transaction
|
Acquisition by Darhold Limited of 155,991 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%. |
c) |
Price(s) and volume(s) |
Price(s): £21.94 Volume(s): 155,991 |
d) |
Aggregated information |
Aggregated volume: 155,991 Price: £21.94 |
e) |
Date of the transaction |
6 September 2016 |
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Mohammed 'Ali' Al-Husry
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
Mohammed 'Ali' Al-Husry |
2 |
Reason for the notification |
|
a) |
Position/status |
Non-executive Director/ PDMR |
b) |
Initial notification /Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Hikma Pharmaceuticals PLC |
b) |
LEI |
549300BNS685UXH4JI75 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
b) |
Nature of the transaction
|
Acquisition by Darhold Limited of 155,991 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%. |
c) |
Price(s) and volume(s) |
Price(s): £21.94 Volume(s): 155,991 |
d) |
Aggregated information |
Aggregated volume: 155,991 Price: £21.94 |
e) |
Date of the transaction |
6 September 2016 |
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Peter Speirs, Company Secretary, Responsible for releasing this announcement
6 September 2016